Cost-effectiveness analysis of lapatinib plus capecitabine versus capecitabine alone in the second line treatment for breast cancer treatment

被引：0
|
作者：
Ejzykowicz, F. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70201-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A60 / A61
页数：2
相关论文
共 50 条
  • [21] Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy
    Bergen, Elisabeth S.
    Berghoff, Anna S.
    Rudas, Margaretha
    Preusser, Matthias
    Bartsch, Rupert
    ANTI-CANCER DRUGS, 2015, 26 (05) : 579 - 581
  • [22] Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
    Reed, Shelby D.
    Li, Yanhong
    Anstrom, Kevin J.
    Schulman, Kevin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) : 2185 - 2191
  • [23] Capecitabine and lapatinib treatment in head and neck cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (07): : E271 - E271
  • [24] Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX plus bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis
    Peria, F. M.
    Ungari, A. Q.
    Dos Santos, F. N.
    Lins-Almeida, T.
    Nunes, A. A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
    S Eggington
    P Tappenden
    A Pandor
    S Paisley
    M Saunders
    M Seymour
    P Sutcliffe
    J Chilcott
    British Journal of Cancer, 2006, 95 : 1195 - 1201
  • [26] Biomarker Analysis of the Phase III NALA Study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
    Saura, Cristina
    Matito, Judit
    Oliveira, Mafalda
    Wildiers, Hans
    Brufksy, Adam M.
    Waters, Simon H.
    Hurvitz, Sara A.
    Moy, Beverly
    Kim, Sung-Bae
    Gradishar, William J.
    Queiroz, Geraldo Silva
    Cronemberger, Eduardo
    Wallweber, Gerald J.
    Bebchuk, Judith
    Keyvanjah, Kiana
    Lalani, Alshad S.
    Bryce, Richard
    Vivancos, Ana
    Eli, Lisa D.
    Delaloge, Suzette
    CLINICAL CANCER RESEARCH, 2021, 27 (21) : 5818 - 5827
  • [27] Comparative effectiveness of trastuzumab emtansine versus lapatinib plus capecitabine for HER2+metastatic breast cancer
    Ramagopalan, Sreeram, V
    Pisoni, Riccardo
    Zenin, Aleksandr
    Rathore, Lokendra Singh
    Ray, Joshua
    Sammon, Cormac
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (07) : 595 - 602
  • [28] Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer
    Franken, M. D.
    van Rooijen, E. M.
    May, A. M.
    Koffijberg, H.
    van Tinteren, H.
    Mol, L.
    ten Tije, A. J.
    Creemers, G. J.
    van der Velden, A. M. T.
    Tanis, B. C.
    Groot, C. A. Uyl-de
    Punt, C. J. A.
    Koopman, M.
    van Oijen, M. G. H.
    EUROPEAN JOURNAL OF CANCER, 2017, 75 : 204 - 212
  • [29] Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
    Eggington, S.
    Tappenden, P.
    Pandor, A.
    Paisley, S.
    Saunders, M.
    Seymour, M.
    Sutcliffe, P.
    Chilcott, J.
    BRITISH JOURNAL OF CANCER, 2006, 95 (09) : 1195 - 1201
  • [30] Capecitabine and bevacizumab (CB) maintenance treatment in metastatic colorectal cancer (mCRC): A cost-effectiveness analysis
    Franken, M.
    Van Rooijen, E.
    Van Tinteren, H.
    May, A.
    Mol, L.
    Ten Tije, A.
    Creemers, G. J.
    Van der Velden, A.
    Van der Torren, A.
    Uyl-de Groot, C.
    Punt, C.
    Koopman, M.
    Van Oijen, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S370
12345